natgillin/translations-raw huggingface dataset:
A compound of formula (IV): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein RM is a reactive moiety and L, V1, Y, Z, p, and z are as defined in claim 1, except that L is now linking RM to one or more V1 and/or Y, and V1, Y, and Z may contain protecting groups, and the one or more V2'-L2' moieties optionally present in Z as defined hereinabove may optionally and independently be RM' instead, which is a reactive moiety, and wherein, if there is more than 1 reactive moiety in (IV), some or all reactive moieties are the same or different. 
[image], ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat, naznačen time što RM je reaktivni ostatak, a L, V1, Y, Z, p i z su definirani kao u patentnom zahtjevu 1, osim što L sada povezuje RM s jednim ili više V1 i/ili Y, a V1, Y i Z mogu sadržavati zaštitne skupine, gdje jedan ili više ostataka V2′-L2′ koji mogu biti prisutni u Z kao što je definirano gore u ovom dokumentu mogu umjesto toga izborno i neovisno biti RM′, koji je reaktivni ostatak, te gdje su, ako je u (IV) prisutno više od 1 reaktivnog ostatka, neki ili svi reaktivni ostaci isti ili različiti.
A compound according to any one of claims 1 to 16 for use as a medicament, in particular for the treatment or prevention of a tumor in a mammal. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time što je namijenjen upotrebi kao medikament, osobito u liječenju ili sprječavanju tumora kod sisavca.
provided that when R1 is unsubstituted phenyl, R2 is not hydrogen. 
uz uvjet da kada R1 je nesupstituirani fenil, R2 nije vodik.
a container (100) formed with a juice discharge port (101); 
spremnik (100) oblikovan s otvorom za ispuštanje soka (101);
a sieve (200) positioned inside of the container (100); 
sito (200) smješteno unutar spremnika (100);
a screw (300) positioned inside of the sieve (200) to extract juice from a material; 
vijak (300) smješten unutar sita (200) za ekstrakciju soka iz materijala;
The juice extraction module according to claim 8, wherein the crushing processing portion (600) covers an entire bottom region of the input portion (410) at the height of the crushing processing portion (600) connected to a bottom end of the input portion (410). 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 8, naznačen time što dio za obradu drobljenjem (600) pokriva cijelo donje područje dijela za ubacivanje (410) u visini dijela za obradu drobljenjem (600) povezanog s donjim krajem dijela za ubacivanje (410).
The juice extraction module according to claim 10, wherein a bottom region of the input portion (410) is positioned to be offset within a semicircle region of a circle having a diameter corresponding to a diameter of the crushing processing portion (600) with a central shaft (310) of the screw (300) as a center. 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 10, naznačen time što je donje područje dijela za ubacivanje (410) tako smješteno da bude ekscentrično unutar polukružnog područja kruga čiji promjer odgovara promjeru dijela za obradu drobljenjem (600) sa središnjom osovinom (310) vijka (300) u središtu.
The juice extraction module according to claim 8, wherein the crushing portion (500) extends to pass over a top end of the sieve (200) and is accommodated in the crushing processing portion (600). 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 8, naznačen time što se dio za drobljenje (500) pruža na takav način da prelazi preko gornjeg kraja sita (200) i nalazi se u dijelu za obradu drobljenjem (600).
Inhaler device (1) of a powdered substance contained in a capsule (2) of the type having an operculum formed of two parts, comprising: 
Aparat za inhalaciju (1) praškaste konzistencije sadržane u kapsuli (2) tipa koji ima poklopac sastavljen iz dva dijela koji obuhvaća:
Inhaler device according to claim 1, wherein each of the two capsule seat parts (14') is suitable for blocking the capsule (2) by interference with walls of the operculum. 
Aparat za inhalaciju prema patentnom zahtjevu 1, pri čemu je svaki od dva sjedišna dijela (14’) kapsule pogodan za blokiranje kapsule (2) interferencijom sa zidovima poklopca.
Inhaler device according to the previous claim, wherein each of the two capsule seat parts (14') is suitable to interfere with the walls of the operculum of the capsule (2) without causing the perforation, punching of said walls. 
Aparat za inhalaciju prema prethodnom patentnom zahtjevu, pri čemu je svaki od dva sjedišna dijela (14’) kapsule pogodan za međusobno miješanje sa zidovima poklopca kapsule (2) a da se ne prouzroči perforacija, probijanje spomenutih zidova.
Inhaler device according to any of the previous claims, comprising capsule extractor means (80), said capsule extractor means being operable to penetrate the two capsule seat parts (14') so as to expel the two parts (2') of the separated capsule (2) after a user has finished inhaling. 
Aparat za inhalaciju prema bilo kojem od prethodnih patentnih zahtjeva, obuhvaća sredstvo (80) za ekstrakciju iz kapsule, spomenuto sredstvo za ekstrakciju iz kapsule imaju funkciju probiti dva sjedišna dijela (14’) kapsule tako da istisnu dva dijela (2’) razdijeljene kapsule (2) nakon što korisnik završi inhaliranje.
Inhaler device according to the previous claim, wherein the capsule seat (14) is in the form of a tray orientated horizontally when the inhaler body (10) is placed on a horizontal surface. 
Aparat za inhalaciju prema prethodnom patentnom zahtjevu, pri čemu je sjedište (14) kapsule u obliku zamjenjivog bloka usmjerenog horizontalno kada se tijelo (10) inhalatora postavi na horizontalnu površinu.
Inhaler device according to the previous claim, wherein each of said support surfaces (54) is formed of an inclined plane with decreasing incline towards the capsule seat (14). 
Aparat za inhalaciju prema prethodnom patentnom zahtjevu, pri čemu se svaka od spomenutih potpornih površina (54) formira od pognute ravnine s nagibom koji se smanjuje prema sjedištu (14) kapsule.
triflating a compound of formula in the presence of a base to give a compound of formula 
trifliranje spoja formule [image] u prisutnosti baze kako bi se dobio spoj formule [image]
A process according to one of claims 1 to 4, wherein in step a) the compound of formula (V) is added simultaneously with 1 equivalent of an organic base and 1.1 equivalent of triflic anhydride. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se u koraku a) spoju formule (V) istodobno doda 1 ekvivalent organske baze i 1,1 ekvivalent anhidrida trifluormetansulfonske kiseline.
deprotecting the compound of formula (IV) to produce compound of formula (I). 
uklanjanje zaštite spoja formule (IV) kako bi se dobio spoj formule (I).
The process according to claim 4, wherein step (b) is performed in the presence of an acid. 
Postupak prema zahtjevu 4, u kome se korak (b) provodi u prisutnosti kiseline.
iii) reacting the compound of formula (VII) with a reducing agent to produce compound of formula (II). 
iii) reakciju spoja formule (VII) s redukcijskim sredstvom kako bi se dobio spoj formule (II).
The process according to any of claims 1 to 5, wherein the compound of formula (II) is obtained by a process comprising the steps of reacting a compound of formula (V) with a silylating or an acylating agent to produce compound of formula (Va), wherein P1 has the same meaning as in claim 1; 
Postupak prema bilo kojem od zahtjeva 1 do 5, u kome se spoj formule (II) dobiva postupkom koji obuhvaća korake 1) reakciju spoja formule (V) sa sililirajućim ili acilirajućim sredstvom kako bi se dobio spoj formule (Va), pri čemu P1 ima isto značenje kao u zahtjevu 1;
dehalogenation or desulfinylation of the compound of formula (Vb) to produce compound of formula (V); and 
dehalogeniranje ili desulfoniranje spoja formule (Vb) kako bi se dobio spoj formule (V); i [image]
reacting the compound of formula (VII) with a reducing agent to produce compound of formula (II). 
reakciju spoja formule (VII) sa redukcijskim sredstvom kako bi se dobio spoj formule (II).
The process according to claim 9, wherein step (2) is a sulfinylation and the sulfinylation is performed by reacting the compound of formula (Va) with a base and with a sulfinylation reagent. 
Postupak u skladu sa zahtjevom 9, u kome je korak (2) sulfoniranje a sulfoniranje se izvodi reakcijom spoja formule (Va) sa bazom i reagensom za sulfinilaciju.
The process according to claim 9, wherein step (2) is a halogenation and the halogenation is performed by reacting the compound of formula (Va) with a halogenating reagent. 
Postupak u skladu sa zahtjevom 9, u kome je korak (2) halogeniranje a halogeniranje se izvodi reakcijom spoja formule (Va) sa reagensom za halogeniranje.
Composition comprising red blood cells encapsulating a peptidic or proteic active principle selected from the group consisting of: 
Pripravak koji sadrži crvene krvne stanice koji enkapsulira peptidni ili proteinski aktivni sastojak odabran iz skupine koju čine:
Composition for the use according to claim 4, wherein the lysosomal enzyme is an enzyme for replacement therapy (ERT) in pompe disease (Glycogen storage disease type II), Fabry disease or Mucopolysaccharidoses disorders MPS I. 
Pripravak za uporabu prema zahtjevu 4, naznačen time da lizosomni enzim je enzim za zamjensku terapiju (ERT) kod Pompeove bolesti (bolest nakupljanja glikogena tip II), Fabryeve bolesti ili mukopolisaharidoznih poremećaja MPS 1.
Composition for the use according to claim 5, wherein the lysosomal enzyme is selected from the group consisting of alphaglucosidase enzyme, laronidase and alphagalactosidase A and agalsidase alpha. 
Pripravak za uporabu prema zahtjevu 5, naznačen time daje lizosomni enzim odabran iz skupine koju čine enzim alfaglukozidaze, laronidaze i alfagalaktozidaze A i agalzidaze alfa.
Composition for the use according to claim 9, wherein the active principle is against Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Juvenile diabetes, Uveitis, an inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, psoriasis, or acquired myasthenia gravis. 
Pripravak za uporabu prema zahtjevu 9, naznačen time da aktivni sastojak je protiv reumatoidnog artritisa (RA), multiple skleroze (MS), juvenilnog dijabetesa, uveitisa, upalne bolesti crijeva, Crohnove bolesti, ulcerativnog kolitisa, sistemskog eritemskog lupusa, psorijaze, ili stečene mijastenije gravis.
Composition for the use according to claim 9, wherein the active principle is myelin basic protein against Multiple Sclerosis (MS), the Beta-cell antigen, the pro-insuline, the insuline-like growth factor-2 (IGF2) or mixtures thereof against Juvenile diabetes, the retinal-S antigen against Uveitis, or acetyl choline receptor against acquired myasthenia gravis. 
Pripravak za uporabu prema zahtjevu 9, naznačen time da aktivni sastojak je mijelinski bazični protein protiv multiple skleroze (MS), antigen Beta-stanice, pro-inzulin, inzulinu sličan faktor rasta-2 (IGF2) ili njihove smjese protiv juvenilnog dijabetesa, retinalni-S antigen protiv uveitisa, ili receptor acetil kolina protiv stečene mijastenije gravis.
Composition for the use according to claim 1, wherein the active principle is a transplantation peptidic or proteic antigen, and the composition of red blood cells containing said antigen is against graft rejection, preferably kidney, heart or liver graft rejection. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da aktivni sastojak je transplantacijski peptidni ili proteinski antigen, te pripravak crvenih krvnih stanica koje sadrže navedeni antigen je protiv odbacivanja presatka, poželjno protiv odbacivanja presađivanja bubrega, srca ili jetre.
Composition for the use according to claim 1, wherein the peptide, polypeptide or protein is one inducing an allergic reaction, and is preferably of food origin. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da peptide, polipeptid ili protein je onaj koji inducira alergijsku reakciju, te je poželjno prehrambenog podrijetla.
Composition for the use according to any one of the preceding claims, wherein the red blood cells (1) contain the active principle and (2) are in the form of an immune complex with an immunoglobulin, preferably an IgG, which recognizes an epitope at the surface of the red blood cells, so as to promote liver targeting. 
Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da crvene krvne stanice (1) sadrže aktivni sastojak i (2) u obliku su imunog kompleksa s imunoglobulinom, poželjno s IgG, koji prepoznaje epitop na površini crvenih krvnih stanica, tako da potiče ciljanje jetre.
Netupitant for use according to claim 1, wherein said netupitant occupies at least 80% of NK1 receptors in the striatum seventy-two hours after said administration. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što navedeni netupitant zauzima najmanje 80% NK1 receptora u striatumu sedamdeset i dva sata poslije navedene primjene.
The wastewater treatment method as claimed in Claim 1, wherein the solid-liquid separation equipment for the sludge within the total oxidization tank is in the form of a sedimentation tank or a filtering equipment. 
Postupak obrade otpadne vode u skladu s patentnim zahtjevom 1, naznačen time što je oprema za razdvajanje krutine od tekućine kod mulja u kompletnom oksidacijskom spremniku u obliku taložnog spremnika ili opreme za filtriranje.
The wastewater treatment method as claimed in Claim 1, wherein the carrier is at least one carrier selected from the group consisting of a gel carrier, a plastic carrier and a fibrous carrier. 
Postupak obrade otpadne vode u skladu s patentnim zahtjevom 1, naznačen time što je nosač najmanje jedan nosač kojeg se bira iz skupine koju čine gelni nosač, plastični nosač i vlaknasti nosač.
The wastewater treatment method as claimed in Claim 5, wherein the carrier is an acetalized polyvinyl alcohol gel. 
Postupak obrade otpadne vode u skladu s patentnim zahtjevom 5, naznačen time što je nosač gel od acetaliziranog polivinil-alkohola.
Use of 2-((1-methylpropyl)amino)ethanol as an additive in an aqueous suspension, containing from 25 to 62 vol. %, based on the total volume of the suspension, of at least one calcium carbonate-comprising material and having a pH of between 8.5 and 11, for increasing the suspension pH by at least 0.3 pH units, wherein the suspension conductivity change is not more than 100 µS/cm per pH unit, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, per liter of the aqueous phase of said suspension. 
Postupak povećavanja pH vodene suspenzije koja sadrži 25 do 62 vol.% barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 i 11, naznačen time da postupak uključuje korak dodavanja 2-((1-metilpropil)amino)etanola u suspenziju u količini za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 µS/cm po jedinici pH, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 15000 mg, po litri vodene faze navedene otopine.
Use according to claim 1, characterized in that said 2-((1-methylpropyl)amino)ethanol additive is added as a water based solution to the calcium carbonate-comprising material. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time da je navedeni aditiv 2-((1-metilpropil)amino)etanol dodan kao otopina na bazi vode materijalu koji sadrži kalcijev karbonat.
Use according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity change is not more than 70 µS/cm per pH unit, and preferably is not more than 50 µS/cm per pH unit. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti nije veća od 70 µS/cm po jedinici pH, a poželjno nije veća od 50 µS/cm po jedinici pH.
Use according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity does not change by more than 10 %, preferably does not change by more than 6 %, and more preferably does not change by more than 3 %. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da se nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti suspenzije ne mijenja za više od 10 %, poželjno se ne mijenja za više od 6 %, poželjnije se ne mijenja za više od 3 %.
Use according to any one of the preceding claims, characterized in that said calcium carbonate-comprising material comprises at least 50 %, preferably at least 80 %, and more preferably at least 98 %, by weight of calcium carbonate relative to the total weight of said calcium carbonate-comprising material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da navedeni materijal koji sadrži kalcijev karbonat sadrži najmanje 50 %, poželjno najmanje 80 % i poželjnije najmanje 98 %, po težini kalcijevog karbonata u odnosu na ukupnu težinu navedenog materijala koji sadrži kalcijev karbonat.
Use according to any one of the preceding claims, characterized in that the calcium carbonate of said carbonate-comprising material is a precipitated calcium carbonate (PCC), a natural ground calcium carbonate (NGCC), a surface-reacted calcium carbonate (SRCC), or a mixture thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni materijal koji sadrži kalcijev karbonat istaloženi kalcijev karbonat (PCC), prirodna ruda kalcijevog karbonata (NGCC), površinski-izreagirani kalcijev karbonat (SRCC) ili njihova smjesa.
%, of said calcium carbonate-comprising material based on the total volume of said suspension. 
% navedenog materijala koji sadrži kalcijev karbonat na temelju ukupnog volumena navedene suspenzije.
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added prior to, during or after, and preferably after, a step of grinding said calcium carbonate-comprising material in said suspension. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan prije, za vrijeme ili nakon, poželjno nakon koraka mrvljenja navedenog materijala koji sadrži kalcijev karbonat u navedenu suspenziju.
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to the dry form of said calcium carbonate-comprising material, and is optionally dry ground therewith before forming said suspension of calcium carbonate-comprising material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan suhom obliku materijala koji sadrži kalcijev karbonat i prema izboru je pored toga potpuno osušen prije stvaranja navedene suspenzije materijala koji sadrži kalcijev karbonat.
Use according to claim 17, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is introduced in a container or unit up to a level determined by measurement of the suspension conductivity. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time da se, nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola u navedenu suspenziju, suspenzija dodaje u spremnik ili jedinicu do razine određene mjerenjem vodljivosti suspenzije.
Use according to claim 17, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is passed through a passage having a suspension throughput regulated as a function of the suspension conductivity. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time da nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola u navedenu suspenziju, suspenzija prolazi kroz prolaz koji ima protok otopine reguliran kao funkciju vodljivosti suspenzije.
A liquid pharmaceutical composition as claimed in any of claims 1 to 6 for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis. 
Tekući farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu za liječenje reumatoidnog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, Crohnove bolesti, ulceroznog kolitisa, umjerenom do teške kronične psorijaze i/ili juvenilnog idiopatskog artritisa.
Marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus, characterised in that the viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus, whereby the viral amino acid sequence exhibits at least one of the following substitutions with reference to the C-strain "Riems" virus: 
Marker cjepivo za zaštitno liječenje klasične svinjske groznice sadrži modificirani živi oslabljeni virus svinjske groznice, naznačeno time što virusni aminokiselinski slijed TAV-epitopa proteina E2 obuhvaća slijed različit od divljeg tipa virusa klasične svinjske groznice, tako da aminokiselinski slijed pokazuje najmanje jednu od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
Marker vaccine according to the preceding claim, characterised in that the modified virus does not exhibit recombinant nucleic acid sequences. 
Marker cjepivo u skladu s prethodnim patentnim zahtjevom, naznačeno time što modificirani virus ne izražava rekombinantne sljedove nukleinske kiseline.
Marker vaccine according to any one of the preceding claims, characterised in that the viral nucleotide sequence exhibits one or more of the following substitutions with reference to the C-strain "Riems" virus: 
Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni slijed nukleotida izražava jednu ili više od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
Marker vaccine according to any one of the preceding claims, characterised in that the viral amino acid sequence exhibits one or more of the following substitutions with reference to the C-strain "Riems" virus: 
Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što virusni aminokiselinski slijed izražava jednu ili više od sljedećih supstitucija u odnosu na C-soj „Riems“ virusa:
substitution of amino acid 583; in protein E1; to glutamic acid, 
supstituciju aminokiseline 583; u proteinu E1; glutaminskom kiselinom;
Marker vaccine according to any one of the preceding claims, characterised in that subjects treated with the vaccine can be differentiated from subjects infected with disease-associated swine fever virus via analysis of biological samples obtained from said subjects using serological and/or genomic analytical methods. 
Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što se subjekti tretirani cjepivom mogu razlikovati od subjekata zaraženih virusom svinjske groznice povezanim s bolešću analiziranjem biološkog uzorka dobivenog od navedenih subjekata koristeći serološke i/ili genomske analitičke metode.
Marker vaccine according to the previous claim, characterised in that the genomic analytical method is based upon the polymerase chain reaction (PCR), preferably real-time PCR, whereby primers and/or probes that recognise either the modified and/or disease-associated viral nucleotide sequence are used. 
Marker cjepivo skladu s prethodnim patentnim zahtjevom, naznačeno time što je genomska analitička metoda temeljena na lančanoj reakciji polimeraze (PCR), poželjno PCR u stvarnom vremenu, gdje se koriste početnice i/ili sonde koje prepoznaju bilo modificirani i/ili s bolešću povezani virusni slijed nukleotida.